646 related articles for article (PubMed ID: 22274685)
21. Location of Mutation in
Labidi-Galy SI; Olivier T; Rodrigues M; Ferraioli D; Derbel O; Bodmer A; Petignat P; Rak B; Chopin N; Tredan O; Heudel PE; Stuckelberger S; Meeus P; Meraldi P; Viassolo V; Ayme A; Chappuis PO; Stern MH; Houdayer C; Stoppa-Lyonnet D; Buisson A; Golmard L; Bonadona V; Ray-Coquard I
Clin Cancer Res; 2018 Jan; 24(2):326-333. PubMed ID: 29084914
[No Abstract] [Full Text] [Related]
22. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Rebbeck TR; Mitra N; Wan F; Sinilnikova OM; Healey S; McGuffog L; Mazoyer S; Chenevix-Trench G; Easton DF; Antoniou AC; Nathanson KL; ; Laitman Y; Kushnir A; Paluch-Shimon S; Berger R; Zidan J; Friedman E; Ehrencrona H; Stenmark-Askmalm M; Einbeigi Z; Loman N; Harbst K; Rantala J; Melin B; Huo D; Olopade OI; Seldon J; Ganz PA; Nussbaum RL; Chan SB; Odunsi K; Gayther SA; Domchek SM; Arun BK; Lu KH; Mitchell G; Karlan BY; Walsh C; Lester J; Godwin AK; Pathak H; Ross E; Daly MB; Whittemore AS; John EM; Miron A; Terry MB; Chung WK; Goldgar DE; Buys SS; Janavicius R; Tihomirova L; Tung N; Dorfling CM; van Rensburg EJ; Steele L; Neuhausen SL; Ding YC; Ejlertsen B; Gerdes AM; Hansen Tv; Ramón y Cajal T; Osorio A; Benitez J; Godino J; Tejada MI; Duran M; Weitzel JN; Bobolis KA; Sand SR; Fontaine A; Savarese A; Pasini B; Peissel B; Bonanni B; Zaffaroni D; Vignolo-Lutati F; Scuvera G; Giannini G; Bernard L; Genuardi M; Radice P; Dolcetti R; Manoukian S; Pensotti V; Gismondi V; Yannoukakos D; Fostira F; Garber J; Torres D; Rashid MU; Hamann U; Peock S; Frost D; Platte R; Evans DG; Eeles R; Davidson R; Eccles D; Cole T; Cook J; Brewer C; Hodgson S; Morrison PJ; Walker L; Porteous ME; Kennedy MJ; Izatt L; Adlard J; Donaldson A; Ellis S; Sharma P; Schmutzler RK; Wappenschmidt B; Becker A; Rhiem K; Hahnen E; Engel C; Meindl A; Engert S; Ditsch N; Arnold N; Plendl HJ; Mundhenke C; Niederacher D; Fleisch M; Sutter C; Bartram CR; Dikow N; Wang-Gohrke S; Gadzicki D; Steinemann D; Kast K; Beer M; Varon-Mateeva R; Gehrig A; Weber BH; Stoppa-Lyonnet D; Sinilnikova OM; Mazoyer S; Houdayer C; Belotti M; Gauthier-Villars M; Damiola F; Boutry-Kryza N; Lasset C; Sobol H; Peyrat JP; Muller D; Fricker JP; Collonge-Rame MA; Mortemousque I; Nogues C; Rouleau E; Isaacs C; De Paepe A; Poppe B; Claes K; De Leeneer K; Piedmonte M; Rodriguez G; Wakely K; Boggess J; Blank SV; Basil J; Azodi M; Phillips KA; Caldes T; de la Hoya M; Romero A; Nevanlinna H; Aittomäki K; van der Hout AH; Hogervorst FB; Verhoef S; Collée JM; Seynaeve C; Oosterwijk JC; Gille JJ; Wijnen JT; Gómez Garcia EB; Kets CM; Ausems MG; Aalfs CM; Devilee P; Mensenkamp AR; Kwong A; Olah E; Papp J; Diez O; Lazaro C; Darder E; Blanco I; Salinas M; Jakubowska A; Lubinski J; Gronwald J; Jaworska-Bieniek K; Durda K; Sukiennicki G; Huzarski T; Byrski T; Cybulski C; Toloczko-Grabarek A; Złowocka-Perłowska E; Menkiszak J; Arason A; Barkardottir RB; Simard J; Laframboise R; Montagna M; Agata S; Alducci E; Peixoto A; Teixeira MR; Spurdle AB; Lee MH; Park SK; Kim SW; Friebel TM; Couch FJ; Lindor NM; Pankratz VS; Guidugli L; Wang X; Tischkowitz M; Foretova L; Vijai J; Offit K; Robson M; Rau-Murthy R; Kauff N; Fink-Retter A; Singer CF; Rappaport C; Gschwantler-Kaulich D; Pfeiler G; Tea MK; Berger A; Greene MH; Mai PL; Imyanitov EN; Toland AE; Senter L; Bojesen A; Pedersen IS; Skytte AB; Sunde L; Thomassen M; Moeller ST; Kruse TA; Jensen UB; Caligo MA; Aretini P; Teo SH; Selkirk CG; Hulick PJ; Andrulis I
JAMA; 2015 Apr; 313(13):1347-61. PubMed ID: 25849179
[TBL] [Abstract][Full Text] [Related]
23. Germline BRCA variants, lifestyle and ovarian cancer survival.
Gersekowski K; Delahunty R; Alsop K; Goode EL; Cunningham JM; Winham SJ; Pharoah P; Song H; Jordan S; Fereday S; DeFazio A; Friedlander M; Obermair A; ; ; Webb PM
Gynecol Oncol; 2022 Jun; 165(3):437-445. PubMed ID: 35400525
[TBL] [Abstract][Full Text] [Related]
24. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
25. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract][Full Text] [Related]
26. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN
Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.
Liu J; Cristea MC; Frankel P; Neuhausen SL; Steele L; Engelstaedter V; Matulonis U; Sand S; Tung N; Garber JE; Weitzel JN
Cancer Genet; 2012; 205(1-2):34-41. PubMed ID: 22429596
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
Boyd J; Sonoda Y; Federici MG; Bogomolniy F; Rhei E; Maresco DL; Saigo PE; Almadrones LA; Barakat RR; Brown CL; Chi DS; Curtin JP; Poynor EA; Hoskins WJ
JAMA; 2000 May; 283(17):2260-5. PubMed ID: 10807385
[TBL] [Abstract][Full Text] [Related]
29. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.
Song H; Cicek MS; Dicks E; Harrington P; Ramus SJ; Cunningham JM; Fridley BL; Tyrer JP; Alsop J; Jimenez-Linan M; Gayther SA; Goode EL; Pharoah PD
Hum Mol Genet; 2014 Sep; 23(17):4703-9. PubMed ID: 24728189
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
[TBL] [Abstract][Full Text] [Related]
31. Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study.
Heemskerk-Gerritsen BAM; Hollestelle A; van Asperen CJ; van den Beek I; van Driel WJ; van Engelen K; Gómez Garcia EB; de Hullu JA; Koudijs MJ; Mourits MJE; Hooning MJ; Boere IA
PLoS One; 2022; 17(9):e0275015. PubMed ID: 36137114
[TBL] [Abstract][Full Text] [Related]
32. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
33. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
34. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Lee JS; Wacholder S; Struewing JP; McAdams M; Pee D; Brody LC; Tucker MA; Hartge P
J Natl Cancer Inst; 1999 Feb; 91(3):259-63. PubMed ID: 10037104
[TBL] [Abstract][Full Text] [Related]
35. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
36. Histopathologic features of genetically determined ovarian cancer.
Shaw PA; McLaughlin JR; Zweemer RP; Narod SA; Risch H; Verheijen RH; Ryan A; Menko FH; Kenemans P; Jacobs IJ
Int J Gynecol Pathol; 2002 Oct; 21(4):407-11. PubMed ID: 12352190
[TBL] [Abstract][Full Text] [Related]
37. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
Song H; Dicks E; Ramus SJ; Tyrer JP; Intermaggio MP; Hayward J; Edlund CK; Conti D; Harrington P; Fraser L; Philpott S; Anderson C; Rosenthal A; Gentry-Maharaj A; Bowtell DD; Alsop K; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Høgdall E; Høgdall CK; Jensen A; Kjaer SK; Lubiński J; Huzarski T; Jakubowska A; Gronwald J; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Odunsi K; Goode EL; Menon U; Jacobs IJ; Gayther SA; Pharoah PD
J Clin Oncol; 2015 Sep; 33(26):2901-7. PubMed ID: 26261251
[TBL] [Abstract][Full Text] [Related]
38. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
Birkbak NJ; Kochupurakkal B; Izarzugaza JM; Eklund AC; Li Y; Liu J; Szallasi Z; Matulonis UA; Richardson AL; Iglehart JD; Wang ZC
PLoS One; 2013; 8(11):e80023. PubMed ID: 24265793
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients.
Hasmad HN; Lai KN; Wen WX; Park DJ; Nguyen-Dumont T; Kang PCE; Thirthagiri E; Ma'som M; Lim BK; Southey M; Woo YL; Teo SH
Gynecol Oncol; 2016 May; 141(2):318-322. PubMed ID: 26541979
[TBL] [Abstract][Full Text] [Related]
40. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
